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ABSTRACT
Platinum based drugs are the cornerstone of chemotherapy for ovarian cancer, 
however the development of chemoresistance hinders its success. IL-8 is involved 
in regulating several pro-survival pathways in cancer. We studied the expression of 
IL-8 and IL-8 receptors in platinum sensitive and resistant cell lines. Using qRT-PCR 
and immunohistochemistry, both platinum sensitive (PEA1, PEO14) and resistant 
(PEA2, PEO23) show increased expression of IL-8 and IL-8 receptors. IL-8RA 
shows nuclear and cytoplasmic expression, whilst IL-8RB is present solely in the 
cytoplasm. Knockdown of IL-8 increased sensitivity to cisplatin in platinum sensitive 
and reversed platinum resistance in resistant cell lines, decreased the expression 
of anti-apoptotic Bcl-2 and decreased inhibitory phosphorylation of pro-apoptotic 
Bad. IL-8 receptor antagonist treatment also enhanced platinum sensitivity. Nuclear 
localisation of  IL-8RA was only detected in platinum resistant tumours. Inhibition 
of IL-8 signalling can enhance response in platinum sensitive and resistant disease. 
Nuclear IL-8RA may have potential as a biomarker of resistant disease.
INTRODUCTION
The principal treatment strategy for most 
cases of ovarian carcinoma is primary cytoreductive 
surgery and platinum-based chemotherapy, usually 
using cisplatin or carboplatin along with a taxane 
(e.g paclitaxel). Approximately 75% of patients who 
are initially responsive to chemotherapy can develop 
platinum resistance [1], with a poor outcome for 
patients that is both due to the silent progressive nature 
of ovarian cancer and the development of resistance 
to chemotherapy [2–4]. Among the causes of acquired 
drug resistance in ovarian cancer are secretion of 
molecules that confer resistance [5] and limitation of 
factors required for cancer cell death [6]. The immune 
system is implicated in ovarian cancer progression [7] 
and may also be involved in the acquisition of drug 
resistance via the cytokine and chemokine signalling 
pathways [8].
Interleukin-8 (IL-8) is a pro-inflammatory 
chemokine that is principally a chemoattractant and 
activator of neutrophils during an immune response 
[9]. It also has cell growth, angiogenic and motogenic 
effects in different types of malignancies including 
melanoma, ovarian, prostate, and colon carcinoma 
[10, 11]. The levels of IL-8 are elevated in ovarian cyst 
fluid, ascites, serum, and tumour tissue from patients with 
ovarian cancer [12]. Overexpression of IL-8 in ovarian 
cancer cells increases anchorage-independent growth, 
proliferation, angiogenic potential, adhesion and invasion. 
These effects are decreased on depletion of endogenous 
IL-8 expression by transfecting IL-8-overexpressing 
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SKOV-3 cells with plasmid encoding for antisense 
IL-8 [13]. Studies have shown that high expression of 
IL-8 in ovarian cancer patients is significantly correlated 
with poor prognosis [14, 15], with advanced tumour stage 
and high tumour grade [16].
Experimental studies in prostate carcinoma 
highlighted that IL-8 expression confers 
chemoresistance [17]. Links between resistance to 
chemotherapeutic agents and IL-8 in ovarian carcinoma 
have been previously demonstrated. A paclitaxel-resistant 
ovarian cancer cell line, SKOV-3TR, overexpressed 
a set of genes which included IL-8, suggesting that the 
development of paclitaxel resistance is accompanied 
by multiple changes in gene expression including 
stable alterations in selective chemokine and cytokine 
expression [18]. Also previous studies have shown that 
paclitaxel can induce IL-8 gene expression [19, 20].
The aim of this study was to explore the role of IL-8 
in platinum response in ovarian carcinoma. We show the 
relationship between platinum treatment and expression 
of IL-8 and IL-8 receptors and the relation to platinum 
resistance in ovarian high grade serous carcinoma (HGS) 
both in vitro and in clinical samples.
RESULTS
Expression of IL-8 and IL-8 receptors in 
cell lines
To investigate the in vitro expression and sub-
cellular localisation of IL-8RA and IL-8RB protein 
levels, and the effect of cisplatin treatment on receptor 
expression, sensitive and resistant ovarian high-grade 
serous cancer cells were subjected to cisplatin treatment 
for 24 h and then studied by immunofluorescence and 
confocal microscopy. The intensity of expression and 
localization of receptors were also investigated under 
untreated conditions. The results confirm expression of 
IL-8 receptors in all cell lines tested. The level of receptor 
expression is generally higher in the resistant lines. 
Nuclear localisation of IL-8RA was observed on cisplatin 
treatment in all cell lines (Figure 1).
Examination of the cells at multiple levels using 
confocal microscopy confirms the presence of IL-8RA in 
the nucleus of cells post cisplatin treatment, in contrast to 
IL-8RB, which shows no nuclear localisation. A series of 
optical sections confirms these findings (Figure 2).
Figure 1: Expression of IL-8RA and IL-8RB in ovarian cancer cells pre and post cisplatin treatment. Expression levels 
increase on cisplatin treatment and are generally higher in resistant as compared to sensitive cell lines. Images show cytoplasmic and 
nuclear expression of IL-8RA and cytoplasmic expression of IL-8RB. (Control: negative control; no incubation with primary antibody)
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All cell lines show expression of IL-8 with a rapid 
transcriptional induction of IL-8 following platinum 
exposure, reaching a maximum expression peak of over 
200 fold above baseline following 72 hours exposure, 
reducing back to near basal levels at 96 hours post 
platinum treatment (Figure 3). IL-8 mRNA levels increase 
more rapidly in PEA1 and PEA2 than in PEO14 and 
PEO23. At 48 hours post cisplatin treatment, PEA1 and 
PEA2 cell lines undergo 150–200 fold induction of IL-8 
levels compared to PEO14 and PEO23 which show 95 and 
75 fold induction at 48 hours (Figure 3).
Effect of IL-8 pathway inhibition on cell 
sensitivity to cisplatin
IL-8 was knocked down in the intra-patient paired 
platinum sensitive and resistant cell lines, PEA1/PEA2 
and PEO14/PEO23. Knockdown of IL-8 was confirmed 
by qRT-PCR in all lines.
All cell lines showed a reduction in IL-8 expression 
in siRNA treated cells of > 50% when compared to 
untreated controls. Following cisplatin treatment IL-8 
siRNA treated cells show enhanced apoptotic response to 
Figure 2: Subcellular localisation of IL-8 receptors on cisplatin treatment. Z stack confirms nuclear expression of IL-8RA and 
only cytoplasmic expression of IL-8RB.
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platinum in PEA1 (clinically platinum sensitive, ~2 fold; 
not statistically significant) and PEA2 (clinically platinum 
resistant, > 2 fold; P = 0.0018) cells (Figure 4A).
We sought to further confirm that blocking IL-8 
signalling influences chemoresistance, using an IL-8 
receptor A/B antagonist. Blocking of IL-8 A/B receptors 
re-sensitised PEA2 cells to cisplatin treatment (25 μm), 
as shown by a significant increase in apoptosis (> 3-fold; 
P = 0.0041) compared to the cisplatin only treated cells 
(Figure 4B). This observation mirrors the results obtained 
by siRNA knockdown of IL-8 compared to the non-
targeting control (Figure 4A).
The relationship between IL-8 signalling, 
response to platinum treatment and 
pro-apoptotic proteins
Previous studies have shown that anti-apoptotic 
protein levels are constitutively higher in platinum resistant 
cells. To understand the mechanism of enhancement of 
Figure 3: Expression of IL-8 on platinum treatment in isogenic pairs of platinum sensitive and platinum resistant cell 
lines. There is a consistent trend of increased IL-8 expression up to a peak at 72 hours followed by drop to basal levels around 96 hours in 
both platinum sensitive and resistant ovarian cancer cells.
Figure 4: A. The effect of siRNA for IL-8 on platinum sensitivity. siRNA for IL-8 increases platinum sensitivity in PEA1 and 
reverses platinum resistance in PEA2. B. The effect of blocking IL-8 Signalling using an IL-8RA/RB receptor antagonist: Blocking IL-8 
receptors reverses platinum resistance in PEA2 cells. (cddp = cisplatin) The vertical axis represents fold change in apoptosis.
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platinum response following IL-8 pathway inhibition, 
we studied the levels of two key regulators of apoptosis, 
Bcl-2 and pBad-S136 following IL-8 signalling blockage 
by siIL-8 treatment.
Western blot analysis indicates that knockdown of 
IL-8 causes noticeable reduction of anti-apoptotic Bcl-2 
protein (Figure 5). This observation is mirrored by the 
reduction of inhibitory Bad phosphorylation at S136 
following knockdown of IL-8 compared to the non-
targeting control (Figure 5). Loss of anti-apoptotic proteins 
after IL-8 knockdown and cisplatin treatment explains 
the increase in apoptosis indicated by the elevation of 
caspase activity after IL-8 knockdown and drug treatment 
(Figure 4).
Expression of IL-8 receptors in ovarian high 
grade serous carcinomas
In order to investigate if our in vitro findings 
reflect clinical expression of receptors, we studied the 
expression and subcellular distribution of IL-8RA and 
IL-8RB by immunohistochemistry in 41 high grade 
serous ovarian tumours, which included platinum 
sensitive (n = 17) and resistant tumours (n = 24). 
Expression was seen at variable intensity in the majority 
of tumours (Figure 6). The levels of expression of 
IL-8RA and IL-8RB are presented in tables 1 and 2 
respectively. No statistically significant correlation was 
found between the level of expression of either receptor 
and platinum sensitivity, however, nuclear localisation 
of IL-8RA was seen in 4 cases, all of which were 
platinum resistant (Figure 6D).
DISCUSSION
We previously reported the expression of IL-8 
and IL-8 receptors, IL-8RA and IL-8RB, in benign, 
borderline and malignant epithelial ovarian tumours 
of different histological subtypes. There was also a 
highly significant correlation between IL-8 and IL-8RA 
expression levels and tumour stage, being higher in 
tumours of higher stage and also with tumour type, with 
higher expression in serous carcinoma as compared to 
other histological types [21].
High grade serous carcinoma is the commonest 
type of ovarian cancer [22]. In this study we focused 
on investigating the functional role of IL-8 in platinum 
response in high grade serous carcinoma.
Links between resistance to paclitaxel and IL-8 in 
ovarian cancer cells have been previously reported. The 
paclitaxel-resistant ovarian cancer cell line, SKOV-3TR, 
showed overexpression of IL-8 [18]. Also paclitaxel can 
induce IL-8 gene expression at the transcriptional level 
by activating the IL-8 promoter in human ovarian cancer 
[19, 20].
Wang et al showed that treatment of non-IL-8-
expressing A2780 ovarian cancer cells with exogenous 
recombinant IL-8 and overexpression of cellular IL-8 
induce cisplatin and paclitaxel resistance, while depleting 
endogenous IL-8 expression in IL-8-overexpressing 
SKOV-3 cells using antisense IL-8 transfection promotes 
the sensitivity of the cells to drugs [23]. Their results 
suggest a similar link for cisplatin to IL-8 as has been 
previously reported for paclitaxel. However Domcke et al 
(2013) showed that A2780 and SKOV3 cells are very poor 
models of high grade serous ovarian cancer and therefore 
Figure 5: The effect of IL-8 knockdown on the expression levels of anti-apoptotic proteins. IL-8 knockdown by siRNA 
causes reduction of expression of total Bcl-2 protein and in phosphorylation of Bad at serine residue 136. Both of these events are associated 
with pro-apoptotic signalling. (cddp = cisplatin)
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the relevance of IL-8 in the response to platinum in the 
common high grade serous subtype remains unanswered. 
The cell lines used in this study were derived directly from 
the malignant ascites or pleural effusions of high grade 
serous cancer patients treated at the Western General 
Hospital in Edinburgh, UK and are very well annotated for 
clinicopathological features and chemotherapy response 
(described in Cooke and Brenton (2010)).
Figure 6: Expression of IL-8 receptors RA and RB in ovarian high grade serous carcinoma. The receptors are expressed 
at variable intensity in tumours. IL-8RA showed weak (A), moderate (B) and strong expression [magnification ×100]. Some cases 
showed nuclear localisation of IL-8RA (D) [magnification ×400]. IL-8RB showed weak (E), moderate (F) and strong (G) expression 
[magnification ×100]. (H) Negative control [magnification ×400]
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In the present study we further explored this link 
using these intra-patient paired platinum sensitive and 
platinum resistant ovarian cancer cell lines that normally 
express IL-8 and IL-8 receptors. We show for the first 
time that in these clinically derived HGS cells the 
expression of IL-8 is enhanced by platinum treatment, 
and that this increased expression is consistent in all 
4 studied cell lines, reaching a peak at 72 hours post 
treatment and then declining to baseline at 96 hours. Using 
immunocytochemistry we confirmed the expression of 
IL-8 receptors in all cell lines and show that the expression 
of receptors also increased on platinum treatment, with 
a change in subcellular localisation of IL-8RA into the 
nucleus. This is also the first study demonstrating that 
treatment with chemotherapeutic agents not only increases 
expression of IL-8, but also influences the level of 
expression and subcellular localisation of IL-8 receptors. 
The results show a significant link between treatment with 
cisplatin and enhancing IL-8 signalling activity through 
upregulation of expression of both ligand and receptors. 
The high expression of IL-8 in the presence of increased 
IL-8 receptor expression would set a circuit for autocrine 
and paracrine signalling [24], which is known to increase 
tumour cell growth, survival, migration and angiogenesis 
[25] and as we show platinum resistance and upregulation 
of anti-apoptotic proteins. These facts highlight IL-8 
and IL-8 receptors as potential therapeutic targets in 
management of ovarian tumours.
Our results show that knocking down IL-8 by siRNA 
enhances sensitivity to platinum in the platinum sensitive 
cell line PEA1 and reverses platinum resistance in the 
platinum resistant cell line PEA2. This is demonstrated 
by increase in apoptosis as compared to controls 
represented by untreated cells or cells treated with non-
targeting siRNA. Platinum resistance in PEA2 was also 
reversed using an IL-8 receptor blocking agent/antagonist. 
This provides promise for the clinical use of anti-IL-8 
receptor agents in treatment of platinum resistant cases 
in conjunction with platinum based chemotherapeutic 
agents to improve drug sensitivity. Knowing the time 
line of the rise of IL-8 expression in HGS cells following 
platinum treatment as shown in this study helps making 
informed plans as to the optimal time of the concurrent 
administration of different agents.
It is well established that the effect of platinum 
on cells is principally mediated through its reaction 
with cellular DNA to cause damage, which finally triggers 
the cell’s apoptotic pathway. Previous work in our lab has 
identified that platinum mediated DNA damage leads to 
a DNA-PKcs dependent activation of pro-survival AKT 
signalling , however this happens in platinum resistant 
cells only [26]. The data provided here indicates that the 
role of IL-8 in platinum response is independent of this 
mechanism as inhibition of IL-8 signalling appears equally 
effective at enhancing response in platinum sensitive and 
resistant cell lines, using the same cell line models as our 
previous study.
Changes in the level of expression or activity of 
apoptosis related proteins is one of the mechanisms 
of development of platinum resistance [27]. We hence 
explored the effect of knocking down IL-8 on the 
level of 2 anti-apoptotic proteins; bcl-2 and pBAD. 
Our results show the downregulation of both proteins 
following knock down of IL-8. The findings are in 
Table 1: expression of IL-8RA in ovarian high grade serous carcinoma
 Resistant Sensitive Total
0 2 0 2
1 8 4 12
2 8 8 16
3 6 5 11
Total 24 17 41
P-Value 0.513278
Table 2: expression of IL-8RB in ovarian high grade serous carcinoma
 Resistant Sensitive Total
0 0 0 0
1 8 4 12
2 11 12 23
3 4 0 4
Total 23 16 39
P value 0.118982278
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agreement with Wang et al. who demonstrated that 
the chemoresistance caused by IL-8 is associated 
with increased expression of apoptosis inhibitory proteins 
(Bcl-2, Bcl-xL, and XIAP) [23].
IL-8 mediates its biological effects via the two 
receptors, IL-8RA and IL-8RB. IL-8RA binds to 
granulocyte chemotactic protein-2 and IL-8 only. In 
contrast IL-8RB is more promiscuous and in addition 
to IL-8 is activated by several chemokines including 
Gro-α, β and γ, neutrophil activating peptide and 
granulocyte activation peptide-2 [28]. Our in vitro work 
showed that nuclear localisation of IL-8RA is precipitated 
by platinum treatment in the different cell lines. On 
studying tumour samples by IHC we found no correlation 
between the level of expression of IL-8 receptors and the 
status of platinum sensitivity of the tumours. However, 
nuclear IL-8RA expression was only found in platinum 
resistant tumours. The results suggest the detection of 
nuclear expression of IL-8 in an ovarian high grade serous 
carcinoma may be a potential marker for identifying a 
sub-population of platinum resistant tumours. The fact 
that cisplatin treatment increases expression of IL-8 
and that decreased expression of IL-8 is associated with 
decrease and / or reversal of resistance suggest that it 
plays a role in resistance. Provisionally in vitro work 
shows that on increase of expression there is nuclear 
localisation. As increased expression in vitro is associated 
with nuclear localisation, it may be extrapolated that 
nuclear localisation can be a marker of resistance or 
decreased platinum sensitivity. In the small number of 
tumours studied, we only detected nuclear localisation in 
resistant cases. This is an initial observation suggesting 
that nuclear localisation of IL-8RA may be a potential 
biomarker for resistance. However, as the number of cases 
studied is small, a larger cohort with known response to 
platinum treatment needs to be tested to validate this 
observation.
In conclusion, our results show that IL-8 and IL-8 
receptor expression by tumour cells increases on cisplatin 
treatment, and that IL-8 knockdown increases the cells’ 
sensitivity to cisplatin. The effect of IL-8 on platinum 
sensitivity appears to be mediated via an effect of IL-8 on 
anti-apoptotic proteins Bcl-2 and Bad. Our results form 
the basis for preclinical and clinical assessment of IL-8 
and IL-8 receptors as therapeutic targets in conjunction 
with platinum based therapy.
MATERIALS AND METHODS
Cell lines and reagents
Intra-patient paired platinum sensitive and resistant 
high grade serous ovarian carcinoma cell lines (PEA1 vs 
PEA2 and PEO14 vs PEO23 respectively) were obtained 
from Dr. Simon Langdon (Edinburgh, UK) [29]. The cell 
lines PEA1 and PEO14) were derived prior to the onset 
of platinum resistance, whereas PEA2 and PEO23 were 
derived following acquired clinical platinum resistance 
and were cultured and maintained in RPMI-1640 medium, 
supplemented with 10% foetal calf serum, 1% Penicillin 
Streptomycin and L-Glutamine (all GIBCO, UK) at 
37°C/5% CO2.
Antibodies used were IL-8-RA/CXCR1 and IL-8-
RB/CXCR2 (R&D systems, UK); Alexa Fluor 594 (BD 
Diagnostics, UK); Bcl-2 and p-Bad S136 (Cell Signalling 
Technology, UK); HSP60 (Abcam, UK); goat anti-
mouse and goat anti-rabbit HRP conjugated secondary 
antibodies (DAKO, Denmark). Blocking of IL-8-RA/B 
Signalling was achieved using a small molecule antagonist 
SCH563705 [30, 31].
Assessment of IL-8 expression during continuous 
exposure to platinum
Matched pairs of platinum sensitive or resistant cells 
were seeded into 6 well plates and incubated for 24 hours. 
Platinum sensitive or resistant cells were treated with 
cisplatin at doses relative to their previously determined 
IC50 concentrations (final concentration 2.5 μM or 
12.5 μM cisplatin respectively) and incubated for 0, 
24, 48, 72 and 96 hours. RNA was prepared from cells 
at each time point using RNeasy mini kit according to 
manufacturer’s protocol (Qiagen, UK). IL-8 levels were 
determined by qRT-PCR as described below.
siRNA transfection, apoptosis and cell 
viability assays
The matched cell line pairs, PEA1/PEA2 
and PEO14/PEO23, were transfected with siRNAs 
directed to IL-8 or non-targeting control 2 (NT2) (GE 
Dharmacon, USA) at 60% confluency and re-transfected 
48 hours later. Cells were transfected with siRNAs at 
final concentration of 100 nM using DharmaFECT 
1 transfection reagent (GE Dharmacon, USA) according 
to manufacturer’s instructions. Twenty-four hours after 
second transfection, cells were reseeded into 6 well 
plates and incubated for 48 hours. Cell lysates were 
collected and RNA extracted using RNeasy mini kit 
according to manufacturer’s protocol (Qiagen, UK). 
Caspase activation was measured using Caspase 3/7 Glo 
assay (Promega, UK) and activity normalised to cell 
viability inferred by MTT assay, performed as described 
elsewhere [26, 32].
Reverse transcription and determination of gene 
expression using quantitative real-time PCR
cDNA was synthesised using 1 μg of total RNA, 
1 μl oligodT primer (0.5 μg/μl) (Life Technologies, UK) 
1 μl RNasin, 4 μl 5x MMLV buffer, 1 μl 10 mM dNTP mix 
and 0.3 μl of MMLV reverse transciptase (Promega, UK) 
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made up to a final volume of 20 μl with RNase free 
water. Reactions were incubated at; 65°C for 10 minutes 
and chilled to 4°C for 5 minutes. Reactions were then 
incubated for a further hour at 37°C, stopped by heating to 
95°C for 5 minutes, then cooled to 4°C.
Real time PCR master mix consisted of; 5 μl 
Faststart Universal SYBR Green Master (Rox) 
(Roche, UK), 1 μl of each forward and reverse primers 
at 12.5 μM (Life Technologies, UK), 1μl RNase free 
water, 2 μl cDNA. PCR cycling parameters were as 
follows; 95°C 10 mins, 95°C 10 secs, 60°C 30 secs 
for 40 cycles and run on 7900HT Fast Real-Time PCR 
System (Applied Biosystems). Gene expression data 
was normalised in all reactions to its endogenous 
peptidylprolyl isomerise A (PPIAs) control. mRNA levels 
of cisplatin treated cells were normalised to untreated 
cells to obtain the net value in mRNA expression after 
platinum treatment. Primer sequences were as follows: 
PPIA Forward- 5′-TGCTGTATTGTTGCCCATGT-3′; 
PPIA Reverse -5′-GATCAAATCCGCCACCTCTA-3′; 
IL-8 Forward – 5′-CTTGTCATTGCCAGCTGTGT-3′; 
IL-8 Reverse – 5′-TGACTGTGGAGTTTTGGCTG-3′.
Blocking of IL-8 signalling using IL8RA/RB 
antagonist
The IL-8RA/RB antagonist SCH563705 [30, 31] 
was used at a final concentration of 100 nM. Matched 
platinum sensitive and resistant cell lines PEA1 and 
PEA2 were seeded at a density of 1 × 104 per well in 
96 well plates or 2 × 105 per well in 6 well plates and 
treated with the antagonist alone and/or cisplatin (10 μM 
(PEA1) or 25 μM (PEA2)) for 24 hours. Apoptosis and 
cell viability assays were carried out as described above. 
Cell lysates were prepared for both RNA and protein 
extraction.
Determination of pro-apoptotic protein levels by 
Western blotting
Cells subjected to IL-8 siRNA were harvested 
and lysed in radioimmunoprecipitation (RIPA) assay 
buffer (Santa Cruz Biotechnology, USA) including 
1% phosphatase inhibitor, protease inhibitor and 
sodium orthovanadate. Protein lysates were run 
on SDS-polyacrylamide gels and blotted onto 
nitrocellulose membrane (Pall Corporation, USA). 
Following transfer, membranes were blocked in 5% 
bovine serum albumin (BSA) in TBS-Tween, probed 
with antibodies for HSP60, Bcl-2 or p-Bad S136 at 
a dilution of 1:1000 in 5% BSA/TBS-T overnight 
at 4°C, washed three times in TBS-T, incubated in 
corresponding secondary antibodies for 1 hour at room 
temperature, washed three times, and bound antibodies 
visualized by Immobilon enhanced chemiluminesence 
(Millipore, UK).
Immunofluorescence and confocal microscopy
Cells were grown on coverslips for 24 hours at a 
concentration of 1 × 104 for PEO1, PEA2, PEO14, PEO23 
cells, at 3 × 104 for PEO4 and 9 × 103 for PEA2 cells 
respectively. Cells were treated with either cisplatin for 
24 hours at a concentration of 5 μM for platinum sensitive 
and 25 μM for platinum resistant cells or media only 
(untreated). Cells were fixed with 4% paraformaldehyde 
for 30 min at 37°C and rendered permeable in 0.2% triton. 
Coverslips were washed with PBS and blocked in 2% 
FCS/1% BSA solution for 30 min at 37°C. Cells were 
incubated with the primary antibody for IL-8RA (1:2000) 
or IL-8RB (1:200) for 1 hour at 37°C. After rinsing in 
PBS, the cells were incubated in the secondary antibody 
Alexa Fluor 594 (1:600) for 1 hour at 37°C. For negative 
control experiments, cells were similarly treated with 
the primary antibody omitted. Cover slips were affixed 
to slides with mounting media containing DNA-binding 
DAPI dye (Vectashield, Vector Labs, UK). Cells were 
examined with a Zeiss LSM 510 confocal microscope, 
using an x63 oil immersion lens.
Immunohistochemistry for IL-8RA and IL-8RB 
expression in platinum sensitive and resistant 
ovarian tumours
Forty-one ovarian tumours, all high grade serous 
carcinoma, were studied. Seventeen tumours were from 
confirmed platinum sensitive and 24 from platinum 
resistant patients who underwent surgery and received 
treatment at the Hammersmith Hospital, London, United 
Kingdom. Tumour specimens were available as formalin 
fixed, paraffin embedded tissue blocks. All slides were 
reviewed and representative blocks of the tumours were 
selected for the study. Ethics committee approval was 
obtained from Hammersmith and Queen Charlotte’s and 
Chelsea Research Ethics Committee (REC reference: 05/
Q0406/178).
The expression of IL-8RA and IL-8RB was 
investigated using an indirect two-stage method. Tissue 
sections were de-waxed and rehydrated by passing the 
slides through xylene and descending grades of alcohol 
then water. Slides were then incubated for 15 minutes with 
0.6% hydrogen peroxide solution to block endogenous 
peroxidase activity, followed by heat-mediated 
antigen retrieval, using 0.1M citrate buffer pH 6.0 and 
microwaving for 20 minutes. Slides were then attached to 
a sequenza racks. To block non-specific binding 100 μl of 
Protein Block were added to each slide for 5 minutes and 
the slides were incubated with 100 μl of the corresponding 
primary antibody (1:8000 for IL-8RA and 1:400 for IL-
8RB) at 4°C overnight.
Slides were washed with 0.05% PBS/ Tween 
20 solution, followed by 5 minutes incubation with 
100 μl of post primary block. After another wash, the 
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slides were developed with the addition of 100 μl 3, 
3′-Diaminobenzidine (DAB) solution followed by 
counterstaining with haematoxylin.
Slides were then dehydrated in ascending grades 
of alcohol, cleared with xylene and mounted using Di-N-
Butyle Phthalate in Xylene (DPX) mountant and covered 
with a glass coverslip.
Sections of appendix tissue with acute appendicitis 
were used as a positive control in each run of staining. 
Additionally, the presence of inflammatory cells within the 
test sections acted as further internal positive controls. For 
negative controls, duplicate slides from each case were 
used, and incubated with 100 μl antibody diluent instead 
of primary antibody.
The stained slides were then examined by light 
microscopy to assess the expression and subcellular 
distribution of IL-8RA and IL-8RB. The level of expression 
was scored as weak (1), moderate (2) or strong (3).
Statistical analysis
Statistical analysis of normalised caspase activity 
and gene expression analysis was performed using 
GraphPad Prism® version 5.03. The data represented 
is mean ± standard deviation (SD) or mean ± standard 
error mean (SEM) as indicated. Statistical analysis was 
performed using an upaired, two tailed student’s T-test.
The Chi-square test was used to test for the 
presence of correlations between antigen expression in 
tumours and response to platinum. Significant correlation 
was considered with p ≤ 0.05. Statistical analysis was 
performed using SPSS (version 16.0, Chicago, IL, USA).
ACkNOWLEDGEMENTS
The research was funded by a grant from The Jean 
Shanks Foundation and The Royal College of Pathologists. 
The research was supported by the National Institute for 
Health Research (NIHR) Biomedical Research Centre 
based at Imperial College Healthcare NHS Trust and 
Imperial College London. Dr Euan Stronach is funded by 
Ovarian Cancer Action.
REFERENCES
1. Agarwal R, Kaye SB. Ovarian cancer: strategies for 
 overcoming resistance to chemotherapy. Nat Rev Cancer. 
2003; 3:502–516.
2. Coleman MP, Forman D, Bryant H, Butler J, Rachet B, 
Maringe C, Nur U, Tracey E, Coory M, Hatcher J, 
McGahan CE, Turner D, Marrett L, Gjerstorff ML, 
Johannesen TB, Adolfsson J, et al. Cancer survival in 
Australia, Canada, Denmark, Norway, Sweden, and the 
UK, 1995–2007 (the International Cancer Benchmarking 
Partnership): an analysis of population-based cancer 
 registry data. Lancet. 2011; 377:127–138.
3. McGuire WP. Maintenance therapy for ovarian  cancer: 
of Helsinki and Hippocrates. J Clin Oncol. 2009; 
27:4633–4634.
4. Muggia F. Platinum compounds 30 years after the 
 introduction of cisplatin: implications for the treatment of 
ovarian cancer. Gynecologic oncology. 2009; 112:275–281.
5. Marcu L, Bezak E, Olver I, van Doorn T. Tumour resistance 
to cisplatin: a modelling approach. Physics in medicine and 
biology. 2005; 50:93–102.
6. Kelland L. The resurgence of platinum-based cancer 
 chemotherapy. Nature reviews Cancer. 2007; 7:573–584.
7. Balkwill F. Cancer and the chemokine network. Nature 
reviews Cancer. 2004; 4:540–550.
8. Loose D, Van de Wiele C. The immune system and cancer. 
Cancer Biother Radiopharm. 2009; 24:369–376.
9. Xie K. Interleukin-8 and human cancer biology. Cytokine 
Growth Factor Rev. 2001; 12:375–391.
10. Araki S, Omori Y, Lyn D, Singh RK, Meinbach DM, 
Sandman Y, Lokeshwar VB, Lokeshwar BL. Interleukin-8 
is a molecular determinant of androgen independence and 
progression in prostate cancer. Cancer research. 2007; 
67:6854–6862.
11. Gabellini C, Trisciuoglio D, Desideri M, Candiloro A, 
Ragazzoni Y, Orlandi A, Zupi G, Del Bufalo D. Functional 
activity of CXCL8 receptors, CXCR1 and CXCR2, on 
human malignant melanoma progression. European journal 
of cancer. 2009; 45:2618–2627.
12. Darai E, Detchev R, Hugol D, Quang NT. Serum and cyst 
fluid levels of interleukin (IL) -6, IL-8 and tumour  necrosis 
factor-alpha in women with endometriomas and benign 
and malignant cystic ovarian tumours. Hum Reprod. 2003; 
18:1681–1685.
13. Wang Y, Xu RC, Zhang XL, Niu XL, Qu Y, Li LZ, 
Meng XY. Interleukin-8 secretion by ovarian cancer cells 
increases anchorage-independent growth, proliferation, 
angiogenic potential, adhesion and invasion. Cytokine. 
2012; 59:145–155.
14. Kassim SK, El-Salahy EM, Fayed ST, Helal SA, Helal T, 
Azzam Eel D, Khalifa A. Vascular endothelial growth 
 factor and interleukin-8 are associated with poor prognosis 
in epithelial ovarian cancer patients. Clin Biochem. 2004; 
37:363–369.
15. Mayerhofer K, Bodner K, Bodner-Adler B, Schindl M, 
Kaider A, Hefler L, Zeillinger R, Leodolter S, Joura EA, 
Kainz C. Interleukin-8 serum level shift in patients with 
ovarian carcinoma undergoing paclitaxel-containing 
 chemotherapy. Cancer. 2001; 91:388–393.
16. Merritt WM, Lin YG, Spannuth WA, Fletcher MS, 
Kamat AA, Han LY, Landen CN, Jennings N, De Geest K, 
Langley RR, Villares G, Sanguino A, Lutgendorf SK, 
Lopez-Berestein G, Bar-Eli MM, Sood AK. Effect of 
 interleukin-8 gene silencing with liposome-encapsulated 
small interfering RNA on ovarian cancer cell growth. J Natl 
Cancer Inst. 2008; 100:359–372.
Oncotarget31603www.impactjournals.com/oncotarget
17. Wilson C, Wilson T, Johnston PG, Longley DB, 
Waugh DJ. Interleukin-8 signaling attenuates TRAIL- and 
 chemotherapy-induced apoptosis through transcriptional 
regulation of c-FLIP in prostate cancer cells. Mol Cancer 
Ther. 2008; 7:2649–2661.
18. Duan Z, Feller AJ, Penson RT, Chabner BA, Seiden MV. 
Discovery of differentially expressed genes associated with 
paclitaxel resistance using cDNA array technology: analy-
sis of interleukin (IL) 6, IL-8, and monocyte chemotactic 
protein 1 in the paclitaxel-resistant phenotype. Clin Cancer 
Res. 1999; 5:3445–3453.
19. Lee LF, Haskill JS, Mukaida N, Matsushima K, Ting JP. 
Identification of tumor-specific paclitaxel (Taxol)-
responsive regulatory elements in the  interleukin-8 
 promoter. Molecular and cellular biology. 1997; 
17:5097–5105.
20. Lee LF, Schuerer-Maly CC, Lofquist AK, van Haaften-
Day C, Ting JP, White CM, Martin BK, Haskill JS. Taxol-
dependent transcriptional activation of IL-8 expression 
in a subset of human ovarian cancer. Cancer Res. 1996; 
56:1303–1308.
21. Browne A, Sriraksa R, Guney T, Rama N, Van Noorden S, 
Curry E, Gabra H, Stronach E, El-Bahrawy M. Differential 
expression of IL-8 and IL-8 receptors in benign, borderline 
and malignant ovarian epithelial tumours. Cytokine. 2013; 
64:413–421.
22. Gilks CB, Prat J. Ovarian carcinoma pathology and 
genetics: recent advances. Human pathology. 2009; 
40:1213–1223.
23. Wang Y, Qu Y, Niu XL, Sun WJ, Zhang XL, Li LZ. 
Autocrine production of interleukin-8 confers cisplatin 
and paclitaxel resistance in ovarian cancer cells. Cytokine. 
2011; 56:365–375.
24. Luppi F, Longo AM, de Boer WI, Rabe KF, Hiemstra PS. 
Interleukin-8 stimulates cell proliferation in non-small 
cell lung cancer through epidermal growth factor receptor 
 transactivation. Lung Cancer. 2007; 56:25–33.
25. Singh S, Wu S, Varney M, Singh AP, Singh RK. CXCR1 
and CXCR2 silencing modulates CXCL8-dependent 
 endothelial cell proliferation, migration and capillary-like 
structure formation. Microvasc Res. 2011; 82:318–325.
26. Stronach EA, Alfraidi A, Rama N, Datler C, Studd JB, 
Agarwal R, Guney TG, Gourley C, Hennessy BT, Mills GB, 
Mai A, Brown R, Dina R, Gabra H. HDAC4-regulated 
STAT1 activation mediates platinum resistance in ovarian 
cancer. Cancer Res. 2011; 71:4412–4422.
27. Aggarwal SK. A histochemical approach to the mecha-
nism of action of cisplatin and its analogues. The journal 
of histochemistry and cytochemistry : official journal of the 
Histochemistry Society. 1993; 41:1053–1073.
28. Waugh DJ, Wilson C. The interleukin-8 pathway in cancer. 
Clinical cancer research : an official journal of the American 
Association for Cancer Research. 2008; 14:6735–6741.
29. Langdon SP, Lawrie SS, Hay FG, Hawkes MM, 
McDonald A, Hayward IP, Schol DJ, Hilgers J, 
Leonard RC, Smyth JF. Characterization and properties 
of nine human ovarian adenocarcinoma cell lines. Cancer 
research. 1988; 48:6166–6172.
30. Chao J, Taveras AG, Chao J, Aki C, Dwyer M, Yu Y, 
Purakkattle B, Rindgen D, Jakway J, Hipkin W, Fosetta J, 
Fan X, Lundell D, Fine J, Minnicozzi M, Phillips J, et al. 
C(4)-alkyl substituted furanyl cyclobutenediones as 
potent, orally bioavailable CXCR2 and CXCR1  receptor 
 antagonists. Bioorganic & medicinal chemistry letters. 
2007; 17:3778–3783.
31. Min SH, Wang Y, Gonsiorek W, Anilkumar G, Kozlowski J, 
Lundell D, Fine JS, Grant EP. Pharmacological targeting 
reveals distinct roles for CXCR2/CXCR1 and CCR2 in 
a mouse model of arthritis. Biochemical and biophysical 
research communications. 2010; 391:1080–1086.
32. Stronach EA, Chen M, Maginn EN, Agarwal R, Mills GB, 
Wasan H, Gabra H. DNA-PK mediates AKT activation 
and apoptosis inhibition in clinically acquired platinum 
 resistance. Neoplasia. 2011; 13:1069–1080.
